Japan researchers develop rapid test for deadly tick-borne virus
Baku, June 12, AZERTAC
Researchers at the University of Osaka are developing a rapid diagnostic kit for severe fever with thrombocytopenia syndrome (SFTS), a deadly tick-borne viral disease that a project leader warned could spread nationwide in Japan, Kyodo reported.
The study, being carried out in collaboration with Fujita Health University and the University of Miyazaki, aims to create a test kit capable of delivering same-day results at medical facilities, potentially shortening the time needed to diagnose the disease.
SFTS has a mortality rate of between 10 and 30 percent and can rapidly worsen after symptoms appear, making early diagnosis critical. The disease is mainly spread through the bite of ticks carrying the virus and causes symptoms including fever and vomiting.
According to the Japan Institute for Health Security and other sources, cases have been reported in a number of Asian countries. In Japan, infections have been confirmed since 2013, mainly in western parts of the country.
More than 100 cases have been reported annually in recent years, with elderly people accounting for many of the infections. In 2025, the first reported cases were also recorded in the prefectures of Gifu and Ibaraki as well as Hokkaido, suggesting the geographic spread of the disease.
At present, the primary method used to diagnose SFTS is PCR testing. But the process can take time.
According to the Miyazaki Prefectural Institute for Public Health and Environment, samples from suspected patients must first be sent from medical institutions for testing, and the examination itself can take from half a day to a full day to complete.
While the antiviral drug Avigan is available as a treatment option, doctors say it needs to be administered early for maximum effectiveness.
To speed up the process, researchers are developing a compact diagnostic kit using serum, a component of blood, as the testing sample.
Takayuki Yoshioka, deputy base director at the Center for Advanced Modalities and Drug Delivery System at the University of Osaka and the project leader, said the kit uses an immunochromatographic method that detects reactions between antigens and antibodies.
Like pregnancy or influenza tests, results would be determined visually after a sample is applied to the device, allowing medical workers to quickly identify positive or negative cases.
Researchers are currently investigating antibodies that react sensitively only to SFTS antigens. Multiple candidate antibodies have already been obtained, and prototype kits have been produced.
The project brings together institutions with different areas of expertise. The University of Miyazaki and the Miyazaki Prefectural Institute for Public Health and Environment provide clinical and epidemiological knowledge, while Fujita Health University contributes antibody development technology.
The goal is to create a diagnostic kit that is quick, convenient and highly sensitive.
An official from Miyazaki Prefecture said doctors currently face significant hurdles when they suspect an SFTS infection because testing is not readily available at ordinary medical facilities.
If rapid testing becomes more accessible, patients could receive a diagnosis more quickly without undergoing multiple tests for other suspected illnesses, the official said.
SFTS is also regarded as a growing concern because the virus infects animals including cats and can spread from them to owners and veterinarians.
The University of Osaka describes the illness as a "common, deadly zoonotic disease," and researchers warn that the area affected by the virus is continuing to expand.
"It's only a matter of time before it spreads nationwide," said Yoshioka.
"We have secured most of the necessary materials and are now in the practical application research stage," Yoshioka said. "We hope to complete development as quickly as possible, within one to two years."
The University of Osaka is also planning to develop a vaccine to prevent SFTS infections. Yoshioka said he hopes the university's efforts in both diagnosis and prevention will help reduce deaths caused by the disease.
Other news in this section
